

**i&i**  
Prague

I&I  
BIO




**LET YOUR  
INVENTION  
GROW!**

**BRIDGING  
SCIENCE &  
BUSINESS**

## Institute of Organic Chemistry and Biochemistry (IOCB)

- Leading public research institution in the Czech Republic
- Excellent research & successful applications at the interface of chemical and biological sciences
- Strong track record in technology transfer: successful license agreements with **Gilead Sciences**, Novo Nordisk, Beckmann Coulter, SHINE Medical Technologies
- Significant stream of royalties (\$100 M per year) from license agreements is used to support further research and tech transfer activities – **IOCB Tech, i&i Prague**



# OUR STORY



ÚOCHB  
IOCB PRAGUE

IOCB TEC-H

i&i  
Prague

I&I  
BIO



ÚOCHB  
IOCB PRAGUE

Institute of Organic  
Chemistry and  
Biochemistry

[uochb.cz](http://uochb.cz)

1953

1985

The key-patent  
applications on  
ANP's  
were filed.

2004

Truvada  
(tenofovir-  
disoproxil)  
marketed

2009

IOCB TEC-H

IOCB Tech  
Technology  
Transfer Office

[iocbtech.cz](http://iocbtech.cz)

2015

Genvoya  
(tenofovir-  
alafenamid)  
marketed

2017

i&i  
Prague

i&i Prague  
Biotech incubator &  
investor

[iniprague.com](http://iniprague.com)

2021

I&I  
BIO

i&i Biotech Fund I  
Biotech Investor

[inibio.eu](http://inibio.eu)



# OUR STRUCTURE




ÚOCHB AV  
ČR  
IOCB PRAGUE

IOCB TEC-H

i&i  
Prague

I&I  
BIO



- IOCB = Public research institution
- IOCB Tech = Technology transfer, exclusive to IOCB  
finances from success fees  
100% owned by IOCB
- NF IOCB Tech = Non-profit fund supporting Czech science
- PharmTheon = Laboratory incubator for IOCB drug development projects




# OUR STRUCTURE



ÚOCHB AV ČR  
IOCB PRAGUE

IOCB TEC-H



- IOCB = Public research institution
- IOCB Tech = Technology transfer, exclusive to IOCB  
finances from success fees  
100% owned by IOCB
- NF IOCB Tech = Non-profit fund supporting Czech science
- PharmTheon = Laboratory incubator for IOCB drug development projects
- i&i Prague = BioTech incubator and investor for start-ups and academic projects from CEE
- i&i Bio = EIF-supported VC fund for early-stage CEE BioTech start-ups





**Jiří Moos**  
CEO,  
Board of directors



**Milan Prášil**  
Chairman,  
Board of directors



**Alexandr Krajhanzl**  
Board of directors



**David Stíbal**  
Vice Director



**Iva Machová**  
Project Manager



**Roberto Fernandez**  
Project manager



**Jiří Růžička**  
Project manager



**Martin Kovalčík**  
Communication manager



**Mikuláš Vargic**  
External Lawyer



**Simona Šandová**  
Office manager

MANAGEMENT



**Tomáš Maršálek**  
Partner, CFO



**Karel Kubias**  
Partner, Deals



**Ivan Vohlmuth**  
Partner, Deals



**Jaromír Zahrádka**  
Partner, CEO

TEAM



**Nicolas Beuzen**  
Investment Advisor



**Barbora Šumová**  
Principal



**Pavlína Koutecká**  
Scientific Analyst



**Martin Kovalčík**  
Communication manager



**Mikuláš Vargic**  
External Lawyer



**Simona Šandová**  
Office manager

SUPPORT

**LET YOUR  
INVENTION  
GROW!**

**i&i** Prague  
inventions  
investments



# ABOUT i&i PRAGUE

i&i Prague is a **biotech incubator supporting new inventions**. We do this by **scouting for innovative technologies and helping them to reach the market**.

We help projects to:

- match their technology with a real market need
- secure and protect IP
- coordinate the product and business plan development
- facilitate start-up creation and investment
- eventually, lead the start-ups to Exit


## OUR FOCUS



**DRUG  
DISCOVERY**



**OTHER  
LIFE SCIENCES**



**DIAGNOSTICS**



**MEDTECH**





## Two major roles of i&i Prague:

- 1. Incubation and/or early phase support:** i&i Prague scouts the most promising innovative projects and provides support through the pre-seed and seed phases. **i&i Prague will become a project founder**, helping with legal, business, IP and other aspects throughout the incubation.
- 2. Evaluation and investment:** i&i Prague screens the biotech projects and evaluates the most promising ones for investment eligibility. Since Sep 2021 i&i Prague offers investment via **i&i Biotech Fund**. i&i Prague is responsible for the deep technology, team, market, IP assessment.




Growth  
support


















Industry  
feedback



Investment



# SUPPORTED STARTUPS

 <p><b>DRUG DISCOVERY</b></p>	<p><b>Incubated</b></p>  <p>CASINVENT</p> 	 <p>PEPtherapy</p> 	 <p>Dracen Pharmaceuticals</p> 	 <p>PerioTrap</p> 	 <p><b>MEDTECH</b></p>	<p><b>Incubated</b></p>  <p>LAM</p> 
 <p><b>DIAGNOSTICS</b></p>	 <p>sampling HUMAN</p> 	<p><b>Incubated</b></p>  <p>sophomer</p> 	 <p><b>OTHER LIFE SCIENCES, AI SOFTWARE</b></p>	 <p>Sulfotools</p> 	<p><b>Incubated</b></p>  <p>Deep MedChem</p> 	<p><b>3x</b></p> <p><b>SUCCESSFUL EXIT</b></p>



# BRIDGING SCIENCE & BUSINESS

I&I  
BIO



# ABOUT I&I BIO



**i&i Biotech Fund (i&i Bio) is a venture capital firm investing in innovative early-stage Life Science startups.**

**Established:** 8/2021  
**Fund Size:** € 53 M  
**Geography:** EU, focus on Central Europe  
**Fund Term:** 5+5+3 years  
**Stage:** pre-seed, seed, series A  
**Sweet Spot:** Up to € 2m per project and round  
**Eligibility:** SME

## OUR FOCUS



**DRUG  
DISCOVERY**



**OTHER  
LIFE SCIENCES**



**DIAGNOSTICS**



**MEDTECH**



# OUR INVESTORS



**i&i Prague**  
a commercial subsidiary  
of IOCB Tech



**European  
Investment Fund**



**Česká spořitelna**  
the oldest bank  
in the Czech Republic



**Other investors**  
private and institutional


The Fund is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.



# INVESTED STARTUPS



## DIAGNOSTICS



## OTHER LIFE SCIENCES



## DRUG DISCOVERY



# EVALUATION PROCESS



Our evaluation process usually takes **between 4 and 6 months**.



Evaluated by  
i&i Prague

Shared  
responsibilities



Evaluated by  
i&i Biotech Fund

- Project selection
- Technology evaluation
- Market need, market size
- Competition
- Team evaluation
- IP evaluation
- Expert reviews

- Business plan
- Financial plan

- Legal and financial due diligence
- Investment term sheet
- Investment decision
- Investment execution
- Post investment support



# CASE STUDY



Working group i&i  
Prague –  
MAMA.AI

Management  
completed,  
MAMA.AI and i&i  
Prague  
participation



Deep MedChem

Product on the  
market  
(CHEESE  
platform)

2022

01/2023

06/2023

10/2023

12/2023

05/2024

Collaboration  
project, product  
development

Initial  
negotiations  
about new start-  
up possibility

Preparation of  
business  
plan/direction,  
investment needs  
and expectations,  
IP discussions

Shareholder  
structure agreed,  
financial need for  
first 6 months  
covered

Start-up  
established,  
license  
agreement with  
IOCB signed,  
SHA signed

**Negotiations  
with investors  
(including i&i  
Bio) ongoing**





**Please do not hesitate to  
contact us.**